(Q40903462)

24 September 2017

Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer (English)

1 reference

24 September 2017

11

1 reference

24 September 2017

12

Hartwig Huland

1 reference

24 September 2017

Martina Kluth

1

1 reference

24 September 2017

Frederic Runte

2

1 reference

24 September 2017

Philipp Barow

3

1 reference

24 September 2017

Jazan Omari

4

1 reference

24 September 2017

Zaid M Abdelaziz

5

1 reference

24 September 2017

Lisa Paustian

6

1 reference

24 September 2017

Stefan Steurer

7

1 reference

24 September 2017

Maria Christina Tsourlakis

8

1 reference

24 September 2017

Margit Fisch

9

1 reference

24 September 2017

Markus Graefen

10

1 reference

24 September 2017

Uwe Michl

13

1 reference

24 September 2017

Sarah Minner

14

1 reference

24 September 2017

Guido Sauter

15

1 reference

24 September 2017

Ronald Simon

16

1 reference

24 September 2017

Meike Adam

17

1 reference

24 September 2017

Thorsten Schlomm

18

1 reference

24 September 2017

language of work or name

English

0 references

publication date

22 May 2015

1 reference

International Journal of Cancer

24 September 2017

1 reference

24 September 2017

137

1 reference

24 September 2017

10

1 reference

24 September 2017

2354-2363

1 reference

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

24 September 2017

1 reference

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.

21 January 2018

1 reference

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

21 January 2018

1 reference

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers

21 January 2018

1 reference

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

21 January 2018

1 reference

Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer

21 January 2018

1 reference

Haplo-insufficiency: a driving force in cancer

21 January 2018

1 reference

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

21 January 2018

1 reference

The mutational landscape of lethal castration-resistant prostate cancer

21 January 2018

1 reference

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

21 January 2018

1 reference

Induced chromosomal proximity and gene fusions in prostate cancer

21 January 2018

1 reference

Distinct genomic aberrations associated with ERG rearranged prostate cancer

21 January 2018

1 reference

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

21 January 2018

1 reference

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer

21 January 2018

1 reference

Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness

21 January 2018

1 reference

FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context.

21 January 2018

1 reference

FISH Oracle 2: a web server for integrative visualization of genomic data in cancer research

21 January 2018

1 reference

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis

21 January 2018

1 reference

Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer.

21 January 2018

1 reference

Punctuated evolution of prostate cancer genomes

21 January 2018

1 reference

Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer

21 January 2018

1 reference

The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype

21 January 2018

1 reference

Reduced WWOX protein expression in human astrocytoma

21 January 2018

1 reference

Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro

21 January 2018

1 reference

Cadherins and cancer: how does cadherin dysfunction promote tumor progression?

21 January 2018

1 reference

Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus.

21 January 2018

1 reference

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

21 January 2018

1 reference

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

21 January 2018

1 reference

Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium

21 January 2018

1 reference

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

21 January 2018

1 reference

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29613

1 reference

24 September 2017

1 reference